This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ceresoli, G. L. Articles by Santoro, A. Search for Related Content PubMed PubMed Citation Articles by Ceresoli, G. L. Articles by Santoro, A.

Lung Cancer

Multidisciplinary Treatment of Malignant Pleural Mesothelioma

^aDepartment of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano (Milan), Italy; ^bDivision of Medical Oncology, "S.G. Moscati" Hospital, Avellino, Italy

Key Words. Mesothelioma • Pleural • Malignant • Treatment • Multimodality

Correspondence: Giovanni Luca Ceresoli, M.D., Dipartimento di Oncologia Medica e Ematologia, Istituto Clinico Humanitas IRCCS, Via Manzoni, 56 20089 Rozzano (MI), Italy. Telephone: 0039-02-82244080; Fax: 0039-02-82244590; e-mail giovanni_luca.ceresoli{at}humanitas.it

The incidence of malignant pleural mesothelioma (MPM) is increasing worldwide, and is predicted to peak in the next 10–20 years. Difficulties in MPM diagnosis and staging, especially of early disease, have thwarted the development of a universally accepted therapeutic approach. Single modality therapies (surgery, radiotherapy, chemotherapy) have generally failed to significantly prolong patient survival. As a result, multimodality treatment regimens have been developed. Radical surgery with extrapleural pneumonectomy and adjuvant treatments has become the preferred option in early disease, but the benefits of such an aggressive approach have been questioned because of significant treatment-related morbidity and mortality. In the past few years, there have been several major advances in the management of patients with MPM, including more accurate staging and patient selection, improvements in surgical techniques and postoperative care, novel chemotherapy regimens with definite activity such as antifolate (pemetrexed or raltitrexed)–platinum combinations, and new radiotherapy techniques such as intensity-modulated radiation therapy. Induction chemotherapy followed by surgery and adjuvant radiotherapy has shown promising results. A number of molecular alterations occurring in MPM have been reported, providing broader insights into its biology and leading to the identification of new targets for therapy. However, currently available treatments still appear to have modest results. Further studies are needed to provide evidence-based recommendations for the treatment of early and advanced stages of this disease.

Disclosure of potential conflicts of interest is found at the end of this article.